Clinical Research Directory

Inclusion Criteria: * Minimum age of 18 years old * Histologic diagnosis of pancreatic adenocarcinoma * TNM (7th edition) cT1-4, N0-1, M0-1 * No cytotoxic anti-cancer therapy for advanced / metastatic pancreatic cancer prior to study entry * Ability to provide written informed consent to participate in the study * ECOG performance status 0, 1 or 2. * Patient should have the following blood counts at baseline: ANC equal or greater to 1.5 x 109/L; Platelets equal or greater to 100 x 109/L; Hgb equal or greater to 9g/Dl * Patient should have the following blood chemistry levels at baseline: AST (SGOT), ALT (SGPT) equal or less than 5 x upper limit of normal range (ULN) is allowed * Patient has an identifiable tumor (pancreatic tumor and/or metastasis) by imaging (CT scan and/or MR) * Patient must agree to use contraception considered adequate and appropriate by the investigator and if the patient is female of child-bearing potential, as evidenced by regular menstrual periods, she must have a negative serum pregnancy test (B-hCG) Exclusion Criteria: * Inability to lie supine for more than 30 minutes * Any other type of primary cancer * Life expectancy of less than 12 weeks * Patient has known brain metastases unless previously treated and well controlled for at least 3 months (defined as stable clinically, no edema, no steroids and stable in two scans at least 4 weeks apart) * Patient has serious medical risk factors involving any of the major organ systems